Using oxidant susceptibility of thiol stabilized nanoparticles to develop an inflammation triggered drug release system

2015 ◽  
Vol 3 (8) ◽  
pp. 1597-1604 ◽  
Author(s):  
Faheem Muhammad ◽  
Wenxiu Qi ◽  
Aifei Wang ◽  
Jingkai Gu ◽  
Jianshi Du ◽  
...  

Ultrasmall thiol passivated ZnS NPs are prepared using a newly developed synthetic protocol. Exposure to hydroxyl radicals results in oxidation of the thiol groups, thus destabilizing the ZnS nanolids to open drug encompassing pores for attaining an inflammation responsive drug delivery system.

Author(s):  
Harini Amballa ◽  
Navaneetha Kaluva ◽  
Sree Giri Prasad Beri ◽  
Krishna Mohan Chinnala ◽  
Mayuri Konda

Mucoadhesive drug release system is a preferably unidirectional release system where mucosal epithelial exterior is enclosed by the mucus deposit that interacts with the bio-adhesive drug delivery system and swelling time of the buccal dosage form which is amplified by mucin molecules at the location of administration. Eplerenone is an Anti-hypertensive drug that undergoes hepatic first pass metabolism and shows 69% of bioavailability. In order to bypass the hepatic first pass metabolism the drug is designed to be delivered through buccal cavity to avoid the first pass metabolism. Eplerenone buccal tablets were formulated by using direct compression method with different polymers like HPMC K 100M, Carbopol 934P, Carbopol 974P, Xantham Gum, Eudragit L100 and NaCMC in various concentrations and compositions. Incompatibility complications were not observed from the FTIR spectrums. The formulated and prepared buccal solid dosage forms were evaluated for pre-compressions and post- compression parameters such as hardness, weight variation, thickness, friability, surface pH, swelling index, in-vitro dissolution studies, drug content uniformity, mucoadhesion strength and mucoadhesion time. Evaluation results of formulation F12 are proven to be the optimal formulation showing highest mucoadhesion time, mucoadhesion strength and in-vitro drug release for prolonged period of time about 8 hours. Eplerenone is best delivered through buccal drug delivery system to enhance its oral bioavailability and bypass the hepatic first pass metabolism.


2015 ◽  
Vol 51 (45) ◽  
pp. 9343-9345 ◽  
Author(s):  
Soyeon Park ◽  
Eunjin Kim ◽  
Won Young Kim ◽  
Chulhun Kang ◽  
Jong Seung Kim

A novel biotin-guided anticancer drug delivery system, prodrug 9, consisting of biotin, nitrobenzene, and doxorubicin, with acid-triggered drug releasing capability was synthesized.


2015 ◽  
Vol 3 (37) ◽  
pp. 7401-7407 ◽  
Author(s):  
Haibo Wang ◽  
Gongyan Liu ◽  
Shihua Dong ◽  
Junjie Xiong ◽  
Zongliang Du ◽  
...  

A multifunctional drug delivery system with AIE character was designed and constructed for simultaneous cellular imaging and pH-triggered drug release.


2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Ramakanth Gundu ◽  
Sanjay Pekamwar ◽  
Santosh Shelke ◽  
Deepak Kulkarni ◽  
Santosh Shep

Abstract Background The research was aimed with an approach to formulate biphasic extended-release system of trospium chloride resulting in controlled release of drug up to 24 h with prospects of better control on urinary frequency, efficacy, tolerability, and improved patient compliance. The push–pull osmotic pump (PPOP) bi-layered tablet of trospium chloride (60 mg) was developed with the use of immediate-release polymers in the pull layer (30 mg drug) and polyethylene oxide in the push layer (remaining 30 mg drug). The tablet was formulated by compression after non-aqueous granulation, seal coating, and semipermeable coating. The tablet prepared was laser drilled to create an orifice for drug release. Results Comparative in vitro dissolution and in vivo pharmacokinetic analysis of available marketed formulations demonstrated the complete drug release within 16–18 h; hence the developed biphasic extended-release system has its great importance as it provides zero-order release up to 24 h. Conclusions The developed biphasic extended-release drug delivery system of trospium chloride provides the drug release for 24 h with effective plasma concentration in comparison with the available marketed formulation. Extended release of drug from the developed formulation provides scope for its promising application in the treatment of overactive bladder (OAB).


RSC Advances ◽  
2017 ◽  
Vol 7 (15) ◽  
pp. 9347-9356 ◽  
Author(s):  
Ming Zhang ◽  
Ping Yuan ◽  
Ninglin Zhou ◽  
Yutian Su ◽  
Maoni Shao ◽  
...  

In this study, doxorubicin (DOX) hydrochloride as a model drug, N-doped carbon dots as a drug carrier, and heparin as an auxiliary medicine were selected to design and prepare a multi-functional drug delivery system with pH-triggered drug release.


RSC Advances ◽  
2018 ◽  
Vol 8 (35) ◽  
pp. 19791-19803 ◽  
Author(s):  
Yue Yuan ◽  
Kyoungju Choi ◽  
Seong-O Choi ◽  
Jooyoun Kim

The drug release profiles of doxorubicin-loaded electrospun fiber mats were investigated with regard to drug-polymer miscibility, fiber wettability and degradability.


RSC Advances ◽  
2017 ◽  
Vol 7 (84) ◽  
pp. 53401-53406 ◽  
Author(s):  
Ke Ma ◽  
Yiping Qiu ◽  
Yaqin Fu ◽  
Qing-Qing Ni

Six kinds of nanoscale application are designed in this study. A significant increase of drug release rate can be observed at the gastric site.


2018 ◽  
Vol 6 (8) ◽  
pp. 1216-1225 ◽  
Author(s):  
Tao Zhang ◽  
Yongjia Tang ◽  
Wei Zhang ◽  
Shan Liu ◽  
Yumei Zhao ◽  
...  

A novel injectable and biodegradable cross-linked cyanoacrylate-based local drug delivery system with excellent anticancer activity.


Pharmaceutics ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 212 ◽  
Author(s):  
Keng-Shiang Huang ◽  
Chih-Hui Yang ◽  
Ya-Chin Wang ◽  
Wei-Ting Wang ◽  
Yen-Yi Lu

Vinblastine (VBL) is a major chemotherapeutic drug; however, in some cases, it may cause severe side effects in patients with cancer. Designing a novel VBL pharmaceutical formulation is a crucial and emerging concern among researchers for reducing the use of VBL. This study developed a stimuli-responsive controlled VBL drug release system from magnetically sensitive chitosan capsules. A magnetically responsive controlled drug release system was designed by embedding superparamagnetic iron oxide (SPIO) nanoparticles (NPs) in a chitosan matrix and an external magnet. In addition, droplet microfluidics, which is a novel technique for producing polymer spheres, was used for manufacturing monodispersed chitosan microparticles. The prepared VBL and SPIO NPs-loaded chitosan microparticles were characterized and analyzed using Fourier transform infrared spectroscopy, transmission electron microscopy, scanning electron microscopy, a superconducting quantum interference device, and a biocompatibility test. The drug encapsulation efficiency was 67%–69%. The in vitro drug release test indicated that the VBL could be 100% released from chitosan composite particles in 80–130 min under magnetic stimulation. The pulsatile magnetically triggered tests showed individual and distinctive controlled release patterns. Thus, the timing and dose of VBL release was controllable by an external magnet. The results presume that using a magnetically responsive controlled drug release system offers a valuable opportunity for VBL drug delivery, where the delivery system is an active participant, rather than a passive vehicle, in the optimization of cancer treatment. The proposed actively targeted magnetic drug delivery system offers many advantages over conventional drug delivery systems by improving the precision and timing of drug release, easy operation, and higher compliance for pharmaceutical applications.


Sign in / Sign up

Export Citation Format

Share Document